More recently, E722-2648 was identified in a high-throughput screen for inhibitors of BCL9’s interaction with β-catenin and was shown to reduce WNT target gene expression in human colon cancer organoids and reduce tumour growth in a colon cancer xenograft model [86] Hence, there are promising BCL9 inhibitors that have shown efficacy in various pre-clinical settings and could pave the way for novel treatments in WNT-driven cancers. Here, BCL9 is linked to malignant colon neoplasm.